ArticleDose-response : a publication of International Hormesis Society
Optimal Dose of Lorundrostat in Uncontrolled Hypertension: A Dose Response Meta-Analysis.
Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lorundrostat, an aldosterone synthase inhibitor, shows promise for hypertension management, though optimal dosing strategies remain poorly defined. Aims: To evaluate the efficacy, safety, and dose-response effects of Lorundrostat to identify the optimal therapeutic dose. Methods: We searched PubMed, Embase, Scopus, and ClinicalTrials.gov systematically for relevant RCTs. Using a random-effects model, data were pooled to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CIs). Dose-response modeling was performed using "dosresmeta" and "rcs" packages in R (v4.4.3). Results: Three RCTs (n=1568) were included. Lorundrostat significantly reduced systolic BP at 4-8 weeks (MD: -7.66 mmHg, 95% CI: -10.42 to -4.89) and 12 weeks (MD: -10.19 mmHg, 95% CI: -13.57 to -6.82). Diastolic BP also decreased significantly (MD: -3.81). Sub-group analysis based on background medication count showed no significant differences (P=0.80). Aldosterone levels were significantly reduced (MD: -4.39). Dose-response modeling identified 60 mg as the optimal dose, with diminishing returns thereafter. While hyperkalemia risk increased (RR: 3.19), no significant differences were found in serious adverse events. Conclusion: Lorundrostat effectively lowers BP with a manageable safety profile. The modeling-based insights suggest 60 mg as the optimal dose, delineating a clearer therapeutic window.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.